Regulatory & accrediting organizations require that stored HPC products be labeled with an expiration date. Stem Cell Transplant Program at Children's Memorial Hospital has been collecting HPC, Apheresis products since 1992 with signed donor consent for storage and discard. Though products were labeled with a 5 year expiration date, cells were not discarded until 2006, for want of storage space. We identified 54 products which could be discarded as their intended recipients had died. Products were in liquid nitrogen storage for a period of upto 15.2 yrs. Cells were thawed & viability testing done, as per written procedure. Objective: We undertook this opportunity to discard products to document effect of long term storage on graft cell viability. Method: Donor products were collected by HPC, Apheresis between 1992 Apheresis between & 2003 . Pre-freezing viability done using Trypan Blue Dye Exclusion test was between 96-100% (median 97.3%). Products were mixed with equal quantity of cryoprotectant [3 parts TC-199 without phenol red and 2 parts each of 10% Dimethylsulfoxide (DMSO) and Autologous serum]. Heparin was used as anti-coagulant. Cells were frozen using a controlled rate freezing program and stored in liquid nitrogen. Product bags were thawed in a water bath between 37 -40 o C, gently kneading the contents. Post thaw samples were re-tested for viability, using Trypan Blue. Statistical evaluations were done on SigmaStat 3.5. Result: Table 1 . Post thaw median viability was 90.3% (range68-99%). Of 54 products, 37 products (69%) had viability . 90%; 51 (94%) had viability . 80%; only 3 (6%) had viability below 79%. 15 products (28%) were in storage for \ 3.0 yrs; 12 products (22%) for 3.1 to 5.0 yrs; 12 products (22%) for 5.1 to 10.0 years; & 15 products (28%) were stored for . 10.1 yrs. Statistical evaluations revealed no significant relationship between storage time & cell viability. Discussion: Total nucleated cell viability was measured as an indicator of graft composition. 94% of products retained a viability of . 80% on long term storage. Difference in pre freezing & post thaw median vibility (7%) can be attributed to the freezing process itself. Since HPC, A grafts are capable of engraftment regardless of storage time or percentage of viable cells, stored HPC, A products may actually have a long expiration period. Conclusion: Long term storage of HPC, A products in liquid nitrogen does not result in any significant cell loss and may not need an expiration date. Infusion of allogeneic T cells, administered as donor leukocyte infusions (DLI), has widespread acceptance as immunotherapy for relapsed disease after BMT and as a means of increasing donor chimerism in allogeneic recipients experiencing graft resistance. However, recipients of DLI are at risk of GVHD primarily due to the presence of alloreactive CD45RA1 naive T cells in the infused cells and DLI is not an option for patients who develop GVHD post-transplant. Mouse models indicate that GVHD results primar-ily from naive donor T cells whereas T cells expressing memory phenotypes appear to promote donor chimerism without GVHD. To assess the feasibility of isolating CD81 memory cells from apheresis collections as an alternative to standard DLI, a tandem immunomagnetic selection strategy was used with CD45RA depletion followed by CD8 enrichment. The resulting cells were predominantly CD81/CD45RO1/CD441/CD49d1/CD62L-indicating an effector memory (T EM ) subset. Cytokine secretion by in vitro stimulation with third party cells showed the selected cells produced high levels of IFNg and TNFa but little detectable IL-2, IL-4, or IL10 consistent with the effector memory classification. Post-selection recovery was typically . 200x10 6 cells providing doses of CD81 memory cells comparable to their representation in high dose DLI. A clinical trial to assess the effectiveness of these cells to improve donor chimerism in patients showing graft resistance is planned. Peripheral blood CD341 hematopoietic stem cell (HSC) mobilization with GCSF is the established method for PBSC collection. In 2009 the FDA approved Plerixafor, a CXCR4 antagonist, to enhance mobilization in patients with myeloma and lymphoma. Many patients with PIDs mobilize poorly, limiting autologous PBSC-based treatments. We therefore added plerixafor to our standard mobilization regimen of GCSF, 10 mcg/kg daily for 5 days. Peripheral CD34 counts were assessed on days 4 and 5, and a day 4 CD34 count \ 20 cells/uL was used as criteria for addition of plerixafor 240 mcg/ kg 11 hours prior to apheresis. Targeted CD341 yield was 4 Â 10 6 cells/kg. From 1998 to 2010, 28 PID patients, underwent 48 mobilization cycles (1-6 cycles/patient) during which 83 collections were performed (1-3 aphereses/cycle). 16 of 28 patients received GCSF only during 36 mobilization cycles, undergoing 68 procedures (1.9 procedures/cycle, range 1-3). Mean (6SD) circulating CD34 count on day 5 was 31625 cells/uL (range 2-141) and day 5 product content was 2236208 Â 10 6 CD341 cells, for a cell dose of 4.764.3 Â 10 6 CD34/kg (range 0.3-18). During 16.464.7 liters processed (LP), mean procedure yield was 13.5610 Â 10 6 CD341 cells/LP. 3 patients had such poor mobilization that further apheresis was considered futile. Since adding plerixafor, 9 of 13 mobilizations met criteria for its use. In these, the day 5 CD34 count was 57634 cells/uL (range 15-98) and the day 5 product had 3426295 Â 10 6 CD341 cells (range 55-842), for a cell dose of 9.968.2 Â 10 6 /kg (range 2.2-24). During 15.767.1 LP, mean yield was 20.9614.0 Â 10 6 CD341 cells/LP. 3 patients underwent initial mobilization with GCSF alone, then with plerixafor on a subsequent cycle. In one patient, day 5 CD34 counts were 11 vs 25/uL, respectively, and apheresis yields were 110 vs 231 x10 6 CD34s (5 vs 11.6 x10 6 CD341 cells/LP, and 1.6 vs 3.1 Â 10 6 CD341 cells/kg). In patient two, the day 5 CD34s were 2 vs 15/uL, and product contents were 9 vs 55 Â 10 6 CD34s (0.4 vs 2.2 Â 10 6 CD34/kg). The third patient had undergone multiple GCSF mobilizations, resulting in a mean day 5 CD34 of 41/uL, vs 88/uL with plerixafor. Product content was twice as great with the combination versus GCSF alone. The addition of plerixafor to GCSF more than doubles the peak CD34 mobilization response and apheresis yield of autologous PBSC collections in patients with PIDs and should greatly facilitate PBSC-based treatment strategies. 
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Poster Session I However, the currently used assays (e.g. total nucleated cells, CD341 cells, and viability) do not measure functionality. Enumeration of CFU-GM is generally considered to be the best functional assay, although intra-laboratory variation is high. In addition, CFU-GM measured post cryopreservation are often considerably lower that pre-cryopreservation values. We hypothesized that cryopreserved cord blood stem cells would take longer to recover and grow, so we compared pre-cryo CFU-GM with post-cryo CFU-GM measured after 14, 16, 19 and 21 days in culture on 20 cord blood units. The mean 6 SEM CFU-GM of the fresh cord blood units was 35 6 4.3 Â 10 5 , with 100% viability by trypan blue. The CBU were stored at -195 o C for 4-10 weeks. The mean TNC recovery was 95 613% and viability was 95 6 4%. CFU-GM results on day 14 and 16 of the frozen samples 26% and 17% lower than the fresh cultures (p 5 0.009 and 0.03 respectively). However, the results on day 19 (35 6 4 Â 10 5 ) were equivalent to the fresh (pNS). These data suggest that equivalent pre-and post cryopreservation CFU results can be obtained by allowing the latter more time to recover. Cryopreservation of peripheral blood hematopoietic stem cells (PBHSC) occurs frequently in the setting of autologous stem cell transplantation. The long-term viability of these cells is an important issue as these patients may eventually experience disease relapse. Previous reports have demonstrated that cryopreserved PBHSCs can retain viability for up to 15 years. We describe the effects of long-term cryopreservation on progenitor viability and activity at our institution.
A total of 60 unique PBHSC sample aliquots were evaluated after controlled rate freezing to -90 degrees C. Ten samples were evaluated for viability and activity less than 24 hours after freezing, ten sample were evaluated after 7 years of cryopreservation, thirtyfive samples after ten years of cryopreservation, and five samples after 11 years of cryopreservation. Following culture, product activity was evaluated by microscopy for colony forming unit granulocyte-macrophage-(CFU-GM) and burst forming uniterythrocyte-(BFU-E) colonies. Sample viability was measure by trypan blue assay. Table 1 summarizes the pre-and post-freezing activity and viability for the four groups. We noted significant differences in BFU-E/ kg activity in the controlled rate freezing group (t-test, 95% CI, p 5 0.035), the BFU-E/kg activity in the 7-year samples (t-test, 95% CI, p 5 0.05), the BFU-E/kg activity in the 10-year samples (t-test, 95% CI, p 5 3*10 -5 ), and the BFU-E/kg and CFU-GM/kg activity in the 11-year samples (t-test, 95% CI, p 5 0.032 and 0.038, respectively). There was no significant decrease in the viability of the samples in any of the groups.
Our series demonstrates that long-term freezing of PBHSCs and BMHSCs does not result in a significant decrease in viability of samples but there is a significant negative effect on BFU-E activity at all time points and CFU-GM activity after 11 years. We note a large variability between samples and laboratories (see Table 1 ). Other groups have described stable viability, but reported heterogeneity among CFU-GM and BFU-E activity over time. This may be due to technical skill and method of assay (culture versus flow cytometry). No series has resulted in worse clinical outcomes using cryopreserved product. Use of cryopreserved PBHSCs is an option for selected patients but clinicians should consider collecting more cells than required at the time of harvest and determining the viability and activity of cryopreserved PBHSCs prior to transplantation. Introduction: For numerous malignant and non-malignant hematological diseases allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy. However, a major complication is the acute graft versus host disease (aGVHD), which is life-threatening and substantially reduces efficacy of HSCT. The outcome for patients with severe steroid-resistant aGVHD is very poor. Therefore, it remains important to search for new therapeutic strategies for the treatment of aGVHD.
HEMATOPOIESIS
Objective: Feasibility of the generation mesenchymal stroma cells (MSCs) expanded with human plasma and platelet lysate (hPPL) was tested as well as the feasibility and safety of the application of MSCs in patients with steroid-refractory extensive aGVHD.
Method:
In an open-label, non-randomized prospective phase I/II study MSCs were extracted from the bone marrow of healthy volunteers, expanded with human plasma and platelet lysate (hPPL), and stored. The patients were treated with $2x10 6 /kg MSC. Response rate, transplantation-related deaths, and other adverse events were assessed for up to 12 months after the last infusion of the cells.
Results: Between January 2009 and July 2010, 16 patients were treated; median age 31.6 years (range1.02-60.8). Organ involvement of the aGVHD was 69% skin, 94% gastro-intestinal and 25% liver.
Overall grade was II for 5 (31%), III for 10 (63%), and IV for 1 (6%) patients. 3 patients received 1 dose, 3 patients received 2 doses, all other patients received 3 doses. No patient had side-effects during or immediately after infusions of the MSC. Median follow-up was 188 days (3-643). An objective clinical response was observed in 93% of the patients. CR was observed in 68% patients after a median of 57 days (37-146). One third of the patients with gut aGVHD relapsed (median 140 days after first MSC gift (84-210)). However, GVHD of the gut was then sensitive for the treatment with steroids. Overall, 7 patients died. 3 patients had recurrent malignant disease in the first month after treatment, 2 patients due to progression of aGVHD after reaching a partial remission, 1 patient due to abdominal bleeding and 1 due to unknown cause.
Conclusion: Generation and infusion of MSCs in steroid-resistant aGVHD grade II-IV is a feasible, safe and very effective. In addition, also patients who initially responded to MSCs but develop later a relapse of aGVHD during tapering or cessation of immunosuppressive drugs become again sensitive to the treatment with steroids. 
